Tirzepatide Research & Studies
We track 21 published, PubMed-indexed studies for Tirzepatide, spanning 2021 to 2025. The research below includes 18 clinical trials, 3 meta-analysiss.
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
18
Clinical Trials
3
Meta-Analysiss
Tirzepatide for Obesity Treatment and Diabetes Prevention.
Clinical TrialJastreboff AM, le Roux CW, et al.|N Engl J Med|2025
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
Clinical TrialPacker M, Zile MR, et al.|N Engl J Med|2025
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
Clinical TrialLook M, Dunn JP, et al.|Diabetes Obes Metab|2025
Tirzepatide versus Semaglutide Once Weekly in Patients with Obesity or Overweight (SURMOUNT-5): a head-to-head comparison trial.
Clinical TrialRodriguez PJ, Goodwin B, et al.|N Engl J Med|2025
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Meta-AnalysisKaragiannis T, Malandris K, et al.|Diabetologia|2024
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
Clinical TrialAronne LJ, Sattar N, et al.|JAMA|2024
Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
Clinical TrialZhao L, Cheng Z, et al.|JAMA|2024
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
Clinical TrialMalhotra A, Grunstein RR, et al.|N Engl J Med|2024
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
Clinical TrialLoomba R, Hartman ML, et al.|N Engl J Med|2024
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Clinical TrialNicholls SJ, Bhatt DL, et al.|Am Heart J|2024
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Clinical TrialGarvey WT, Frias JP, et al.|Lancet|2023
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
Clinical TrialHeise T, DeVries JH, et al.|Diabetes Care|2023
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
Clinical TrialWadden TA, Chao AM, et al.|Nat Med|2023
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
Clinical TrialRosenstock J, Frías JP, et al.|JAMA|2023
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
Meta-AnalysisSattar N, McGuire DK, et al.|Nat Med|2022
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Meta-AnalysisKaragiannis T, Avgerinos I, et al.|Diabetologia|2022
Tirzepatide Once Weekly for the Treatment of Obesity.
Clinical TrialJastreboff AM, Aronne LJ, et al.|N Engl J Med|2022
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Clinical TrialDahl D, Onishi Y, et al.|JAMA|2022
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Clinical TrialFrías JP, Davies MJ, et al.|N Engl J Med|2021
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Clinical TrialRosenstock J, Wysham C, et al.|Lancet|2021
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Clinical TrialDel Prato S, Kahn SE, et al.|Lancet|2021